<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321072</url>
  </required_header>
  <id_info>
    <org_study_id>2014/459</org_study_id>
    <secondary_id>2014-003468-19</secondary_id>
    <nct_id>NCT02321072</nct_id>
  </id_info>
  <brief_title>Optimal Oxygenation in the Intensive Care Unit</brief_title>
  <acronym>O2-ICU</acronym>
  <official_title>The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tergooi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. To study the short- and long-term effect of two different PaO2 targets on circulatory&#xD;
           status, organ dysfunction and outcome in patient admitted to the ICU with Systemic&#xD;
           Inflammatory Response Syndrome (SIRS) criteria.&#xD;
&#xD;
        2. To study underlying mechanisms of hyperoxia by determining differences in oxidative&#xD;
           stress response between the hyperoxic and the normoxic patients.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Randomized, prospective multicentre clinical trial&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients admitted to the Intensive Care unit with ≥ 2 positive SIRS-criteria and an expected&#xD;
      ICU stay of more than 48 hours&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Group 1: target PaO2 120 (105 - 135) mmHg (high-normal)&#xD;
&#xD;
      Group 2: target PaO2 75 (60 - 90) mmHg (low-normal)&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
      The primary endpoint will be cumulative daily delta SOFA score (CDDS) from day 1 to day 14.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Contrary to hypoxia, many physicians do not consider hyperoxia harmful for their patients. To&#xD;
      prevent hypoxia, superfluous administration of oxygen is common practice, and hyperoxia is&#xD;
      seen in many patients, especially on Intensive Care units. However, an increasing number of&#xD;
      studies not only confirm the known negative pulmonary effects of chronic oxygen oversupply,&#xD;
      but also important and more acute circulatory effects, characterised by decreased cardiac&#xD;
      output (CO), increased systemic vascular resistance (SVR), and impaired microvascular&#xD;
      perfusion. These phenomena can impair perfusion of organs, which may outweigh higher arterial&#xD;
      oxygen content, resulting in a net loss of oxygen delivery and perturbed organ function. This&#xD;
      may for example be responsible for hyperoxia-associated increased infarct size and increased&#xD;
      mortality after myocardial infarction and cardiac arrest. The underlying mechanisms are not&#xD;
      clarified yet, but probably involve increased oxidative stress with systemic&#xD;
      vasoconstriction.&#xD;
&#xD;
      On the other hand, hyperoxia can also induce several favourable effects. The majority of&#xD;
      ICU-patients have a systemic inflammatory response syndrome (SIRS) with concomitant&#xD;
      vasoplegia due to trauma, sepsis or ischemia/reperfusion injury. Vasoconstriction could&#xD;
      benefit these patients with severe SIRS, reducing the need for intravenous volume&#xD;
      resuscitation and vasopressor requirements. Furthermore, hyperoxia may exert a&#xD;
      preconditioning effect in patients with ischemia/reperfusion injury and prevent new&#xD;
      infections due to its antibacterial properties.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Hyperoxia during SIRS ultimately has unfavourable effects on organ function, especially on a&#xD;
      longer term.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. To study the short- and long-term effect of two different PaO2 targets on circulatory&#xD;
           status, organ dysfunction and outcome.&#xD;
&#xD;
        2. To study underlying mechanisms of hyperoxia by determining differences in oxidative&#xD;
           stress response between the hyperoxic and the normoxic patients.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Randomized, prospective multicentre clinical trial&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients admitted to the Intensive Care unit with ≥ 2 positive SIRS-criteria and an expected&#xD;
      ICU stay of more than 48 hours&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      We will investigate 2 groups with PaO2 targets both within the range of current practice&#xD;
&#xD;
      Group 1: target PaO2 120 (105 - 135) mmHg (high-normal)&#xD;
&#xD;
      Group 2: target PaO2 75 (60 - 90) mmHg (low-normal)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Delta Sequential Organ Failure Assessment Score</measure>
    <time_frame>14 days</time_frame>
    <description>The primary endpoint will be cumulative daily delta SOFA score (CDDS) from day 1 to day 14, calculated as the sum of [daily SOFA score minus admission SOFA score] from day 2 to day 14.&#xD;
Daily SOFA score is calculated as the total of maximum scores for each organ system excluding respiratory system (because of possible PaO2/FiO2 distortion). For patients discharged from the ICU, SOFA score will be registered as 0 from the day of discharge to day 14. Death in the ICU will be registered as a score of 20 (maximum) from the day of death to day 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total maximum SOFA score minus SOFA score on admission</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA rate of decline</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total maximum SOFA score, total maximum SOFA score minus SOFA score on admission, SOFA rate of decline</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>14 days, in-ICU (max 90 days), in-hospital (max 90 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxic events (PaO2 &lt;55 mmHg)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor / Inotrope requirements</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function, fluid balance</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress (F2-isoprostanes)</measure>
    <time_frame>days 1, 3, 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation and ventilator-free days</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay (ICU)</measure>
    <time_frame>average expected 2 to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay (hospital)</measure>
    <time_frame>average expected 10 to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Vascular Resistance Index</measure>
    <time_frame>14 days</time_frame>
    <description>In a random subpopulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>14 days</time_frame>
    <description>In a random subpopulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculatory flow index and Perfused vessel density</measure>
    <time_frame>14 days</time_frame>
    <description>In a random subpopulation. Composite endpoint for two sidestream dark-field microcirculatory measurements.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <arm_group>
    <arm_group_label>High-normal PaO2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-normal PaO2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <arm_group_label>High-normal PaO2</arm_group_label>
    <arm_group_label>Low-normal PaO2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥2 positive SIRS-criteria:&#xD;
&#xD;
               -  Temperature &gt;38 deg.C or hypothermia &lt;36 deg.C&#xD;
&#xD;
               -  Heart rate &gt;90 bpm&#xD;
&#xD;
               -  Respiratory rate &gt;20 /min or pCO2 &lt;32 mmHg (4.3 kPa)&#xD;
&#xD;
               -  Number of leucocytes &gt;12 x 10^9/l of &lt;4 x 10^9/l of &gt;10% bands&#xD;
&#xD;
          -  Within 12 hours of admittance to the ICU&#xD;
&#xD;
          -  Expected stay of more than 48 hours as estimated by the attending physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Elective surgery&#xD;
&#xD;
          -  Carbon monoxide poisoning&#xD;
&#xD;
          -  Cyanide intoxication&#xD;
&#xD;
          -  Methemoglobinemia&#xD;
&#xD;
          -  Sickle cell anemia&#xD;
&#xD;
          -  Severe pulmonary arterial hypertension (WHO class III or IV)&#xD;
&#xD;
          -  Known severe Acute Respiratory Distress Syndrome (ARDS) (PaO2/FiO2 ≤100 mmHg and PEEP&#xD;
             ≥ 5 cm H2O)&#xD;
&#xD;
          -  Known cardiac right to left shunting&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Severe Chronic Obstructive Pulmonary Disease (COPD) (Gold class III or IV) or other&#xD;
             severe chronic pulmonary disease&#xD;
&#xD;
          -  Patients participating in other interventional trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.M.E. de Man, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Angelique Spoelstra-de Man</investigator_full_name>
    <investigator_title>Consultant Intensivist</investigator_title>
  </responsible_party>
  <keyword>oxygen</keyword>
  <keyword>hypoxia</keyword>
  <keyword>hyperoxia</keyword>
  <keyword>critical care</keyword>
  <keyword>intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

